RxDoctor Payments Data

Mehul Patel, MD

Cardiovascular Disease · Newburgh, NYNPI 1467449595

Payments from drug & device makers

$46,842in general payments, 2019–2025

Across 180 payments — averaging $260.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$36K
  • Novartis$5K
  • Boston Scientific$2K
  • Medtronic$644
  • AstraZeneca$371
  • Boehringer Ingelheim$361
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$37,03779%
  • Travel & lodging$1,9954%
  • Food & beverage$7,48816%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,842 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$788,379
Medicare patients
1,502
Services billed
7,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban177$220,037
EliquisApixaban167$212,737
EntrestoSacubitril/Valsartan50$73,176
JardianceEmpagliflozin27$37,517
FarxigaDapagliflozin Propanediol22$23,033
LivaloPitavastatin Calcium16$12,410
Metoprolol Succinate765$11,939
Combivent RespimatIpratropium/Albuterol Sulfate13$5,984
Atorvastatin Calcium552$5,263
Amiodarone Hcl100$3,743
Diltiazem 24hr Er (Cd)Diltiazem Hcl64$3,424
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide205$3,399
Hydralazine Hcl186$2,865
Pitavastatin Calcium20$2,789
Torsemide140$2,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$36,483$220,037177 claims
PfizerEliquis$144$212,737167 claims
NovartisEntresto$4,973$73,17650 claims
Boehringer IngelheimJardiance, Combivent Respimat$361$43,50040 claims
AstraZenecaFarxiga$371$23,03322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Newburgh

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →